https://www.selleckchem.com/products/fl118.html
Over the 96 weeks after switch, mean HBV DNA (P 0.001) but not alanine aminotransferase or CKD stage decreased. Between switch and 96-week follow-up, 11% (26/235) of CKD stage 1 patients migrated to stage 2 and 8% (12/151) of stage 2 patients to stages 3-5, whereas 18% (27/151) from stage 2 to 1, and 19% (7/37) from stages 3-5 to 2. On multivariable generalized estimated equation analysis adjusted for age, sex, hypertension, diabetes, and cirrhosis, baseline eGFR, age (P 0.001), and CKD stages 2 and 3-5 (vs 1) (both P 0.001
Like
Comment
Share
